Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) - Nathan, P; Ascierto, P A; Haanen, J (Eur J Cancer, 2019)